Sight Sciences Inc. (SGHT)
NASDAQ: SGHTHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SGHT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $565.79M
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 3.38 – 11.60
- Day range
- 9.97 – 10.84
- Volume / Avg
- 369.61K / 313.51K
- Beta
- —
- Shares outstanding
- 55.58M
52-week range
SGHT stock today
Sight Sciences (SGHT) closed at $10.18 on Nov 20, down 4.14% (-$0.44), versus the S&P 500's 3.70% decline. At this level, SGHT sits near the top of its 52-week range of $3.38 to $11.60: 12.2% below the high, set on Nov 12, 2026 and 201.4% above the low. SGHT is up 28.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 40.2%.
Sight Sciences has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Sight Sciences
Company profileSight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Paul Badawi
- Headquarters
- Menlo Park, CA
- Employees
- 186
- IPO year
- 2021
- Website
- sightsciences.com
Financial highlights
Full financialsIn fiscal 2025, Sight Sciences generated $77.4 million in revenue, down 3.1% from fiscal 2024, its first annual decline since 2024. Sight Sciences reported a net loss of $38.4 million, compared with a loss of $51.5 million a year earlier. Gross margin was 86.2% (up from 85.5%) and operating margin -48.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $77.36M | $79.87M | $81.06M | $71.33M | $48.96M |
| Growth | -3.13% | -1.47% | +13.63% | +45.70% | +77.12% |
| Net income | $-38.43M | $-51.51M | $-55.55M | $-86.24M | $-62.96M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.14 | $-1.80 | $-2.36 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$12.25+20.33%
- Strong buy 1
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.12 vs $-0.12
- Surprise
- 0.00%
SGHT news
All SGHT news- What Drove Glaukos Stock's 48% Rally Since the End of September?NasdaqGKOS, ALC, ABBV, SGHT
- Sight Sciences Consensus Price Target Raised 10.14% to $11.07Nasdaq
- Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLidsGlobeNewswire
- Sight Sciences signals $92M-$93M 2026 revenue outlook amid higher IDE target of ~$12MSeeking Alpha
- Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire
- HC Wainwright & Co. Initiates Coverage of Sight Sciences with BuyNasdaq
- GKOS Stock Surges 67% Year to Date: What's Driving the Rally?NasdaqGKOS, ALC, ABBV, SGHT
Sight Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TCMDTactile Systems Technology Inc. | 25.60 | -1.50% | $573.48M | vs SGHT |
| RCELAvita Medical Inc. | 15.62 | -2.31% | $494.96M | vs SGHT |
| DCTHDelcath Systems Inc. | 18.79 | -2.34% | $653.67M | vs SGHT |
| CARLCarlsmed Inc. | 17.42 | +1.16% | $477.38M | vs SGHT |
| BVSBioventus Inc. Class A | 9.88 | -0.70% | $676.53M | vs SGHT |
| ANGOAngioDynamics Inc. | 10.81 | +0.46% | $454.61M | vs SGHT |
| MDXGMiMedx Group Inc | 3.05 | -1.93% | $445.07M | vs SGHT |
| SENSSenseonics Holdings Inc. | 8.02 | -9.94% | $439.34M | vs SGHT |
Indexes, lists and sector
Sight Sciences stock FAQ
What is Sight Sciences's stock price today?
SGHT last traded at $10.18 as of Nov 20, 4:00 PM EST, down 4.14% on the day. Prices are delayed at least 15 minutes.
Who is Sight Sciences's CEO?
Mr. Paul Badawi is the chief executive officer of Sight Sciences Inc., which has about 186 employees.
What is the SGHT 52-week high?
The 52-week high for SGHT is $11.60 and the 52-week low is $3.38. The stock is currently 12.2% below its high.